Stockscreener 앱 받기
36.90
0.65%
0.24
시장 영업 전:
36.94
0.04
+0.11%
Royalty Pharma Plc 주식(RPRX)의 최신 뉴스
Ieq Capital LLC Increases Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Stock Position Increased by OMERS ADMINISTRATION Corp - MarketBeat
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - The Manila Times
Leading Biopharma Royalty Investor Royalty Pharma to Join Morgan Stanley Healthcare Conference Sept 9 - Stock Titan
Royalty Pharma PLC $RPRX Position Boosted by American Century Companies Inc. - MarketBeat
Magnetar Financial LLC Buys Shares of 161,496 Royalty Pharma PLC $RPRX - MarketBeat
Adage Capital Partners GP L.L.C. Trims Holdings in Royalty Pharma PLC $RPRX - MarketBeat
What does recent volatility data suggest for Royalty Pharma plc2025 Geopolitical Influence & Community Verified Trade Signals - Newser
Royalty Pharma plc stock outlook for YEARDollar Strength & Low Drawdown Momentum Trade Ideas - Newser
Royalty Pharma plc stock prediction for this weekJuly 2025 Closing Moves & Free Safe Entry Trade Signal Reports - Newser
Royalty Pharma PLC $RPRX Shares Sold by Evergreen Capital Management LLC - MarketBeat
Is Royalty Pharma plc a candidate for recovery playJuly 2025 Trade Ideas & Smart Swing Trading Techniques - Newser
Short interest data insights for Royalty Pharma plcM&A Rumor & Low Risk Entry Point Tips - Newser
Walleye Capital LLC Has $354,000 Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc stock volume spike explainedQuarterly Profit Review & Verified Momentum Watchlists - Newser
What Fibonacci levels say about Royalty Pharma plc reboundPrice Action & Weekly Market Pulse Alerts - Newser
GMT Capital Corp Sells 890,200 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Using economic indicators to assess Royalty Pharma plc potentialJuly 2025 Update & AI Optimized Trading Strategy Guides - Newser
Royalty Pharma plc stock trendline breakdownCEO Change & High Win Rate Trade Tips - Newser
Will Royalty Pharma plc benefit from macro trendsJuly 2025 Outlook & Long-Term Safe Investment Ideas - Newser
Combining machine learning predictions for Royalty Pharma plcMarket Activity Summary & Daily Entry Point Trade Alerts - Newser
Will Royalty Pharma plc stock recover after recent drop2025 Volatility Report & Growth Focused Entry Point Reports - Newser
How to recover losses in Royalty Pharma plc stockDollar Strength & Weekly Setup with ROI Potential - Newser
Is Royalty Pharma plc currently under institutional pressure2025 Pullback Review & Long-Term Investment Growth Plans - khodrobank.com
Compound Planning Inc. Acquires New Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc stock forming a cup and handleJuly 2025 Action & Free High Accuracy Swing Entry Alerts - khodrobank.com
Is Royalty Pharma plc still worth holding after the dipQuarterly Performance Summary & Accurate Technical Buy Alerts - Newser
How to monitor Royalty Pharma plc with trend dashboardsQuarterly Earnings Report & Expert Curated Trade Ideas - Newser
Royalty Pharma PLC $RPRX Shares Sold by BNP Paribas Financial Markets - MarketBeat
Canada Pension Plan Investment Board Sells 151,617 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Applying sector rotation models to Royalty Pharma plcRecession Risk & Long-Term Capital Growth Strategies - Newser
Will Royalty Pharma plc benefit from AI trends2025 Volatility Report & Capital Protection Trading Alerts - khodrobank.com
Royalty Pharma prices $2 billion senior unsecured notes offering - StreetInsider
Is a relief rally coming for Royalty Pharma plc holders2025 Market WrapUp & Safe Entry Point Identification - Newser
Royalty Pharma Prices $2 Billion Debt Offering - MarketScreener
Zenas BioPharma secures $300M funding from Royalty Pharma for obexelimab royalties. - AInvest
Royalty Pharma plc Announces Pricing of $2.0 Billion of Senior Unsecured Notes - MarketScreener
Is Royalty Pharma plc forming a reversal patternMarket Risk Summary & Weekly High Potential Stock Alerts - Newser
Technical signs of recovery in Royalty Pharma plc2025 Big Picture & Free Safe Capital Growth Stock Tips - Newser
How to interpret RSI for Royalty Pharma plc stockJuly 2025 Review & Fast Gaining Stock Reports - Newser
Royalty Pharma prices $2B senior unsecured notes - MSN
Applying Wyckoff theory to Royalty Pharma plc stockGlobal Markets & Real-Time Buy Zone Alerts - Newser
Will breakout in Royalty Pharma plc lead to full recovery2025 Analyst Calls & Fast Entry High Yield Stock Tips - Newser
Can Royalty Pharma plc expand its profit marginsJuly 2025 Final Week & Safe Capital Growth Trade Ideas - khodrobank.com
Royalty Pharma plc recovery potential after sell offEarnings Recap Report & Fast Gain Stock Trading Tips - Newser
Royalty Pharma Prices $2 Bln Offering Of Senior Unsecured Notes - Nasdaq
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes - The Manila Times
$2 Billion Debt Offering: Royalty Pharma Secures Major Financing Across Three Long-Term Tranches - Stock Titan
Royalty Pharma says it announces pricing of $2.0 billion of senior unsecured notes - MarketScreener
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes - GlobeNewswire Inc.
Using data filters to optimize entry into Royalty Pharma plcQuarterly Portfolio Report & Verified High Yield Trade Plans - Newser
Wuxi XDC offers up to 22.3 million shares at HK$58.85 each - AInvest
Using data tools to time your Royalty Pharma plc exit2025 Price Targets & Free Long-Term Investment Growth Plans - Newser
Full technical analysis of Royalty Pharma plc stockWeekly Risk Summary & Precise Trade Entry Recommendations - Newser
What are the analyst revisions for GCLWWIs Royalty Pharma plc stock a good investment in YEARJuly 2025 PostEarnings & Risk Managed Trade Strategies - خودرو بانک
Zenas Biopharma and Royalty Pharma enter into obexelimab funding agreement for up to $300 million - MarketScreener
Zenas BioPharma, Royalty Pharma Enter $300 Million Funding Agreement for Obexelimab - MarketScreener
Zenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab - Nasdaq
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - citybiz
1.75%
1.11%
자본화:
|
볼륨(24시간):